Hepatitis B Virus News and Research

RSS

Scientists develop new test to help identify people at risk for developing liver cancer

Scientists have developed a new test that can help identify people who are likely to develop hepatocellular carcinoma (HCC), the most common form of liver cancer. The approach uses a simple blood test to check for the patient's previous exposure to certain viruses.

11 Jun 2020

Study shows Sofosbuvir alleviates COVID-19-related neurological symptoms

A group of researchers has studied the effects of an antiviral drug Sofosbuvir on human brain organoids infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

2 Jun 2020

Is it safe for SARS-CoV-2 positive mothers to breastfeed?

Even as the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus continues to cause thousands of cases every day, with many deaths, life continues to move on regardless. Births occur as usual, and in many countries, mothers prefer to breastfeed their babies, at least for the first few months of life.

2 Jun 2020

A key player in hepatitis A virus infection discovered

How hepatitis A virus manages to enter liver cells called hepatocytes and initiate infection had remained a mystery for fifty years until now.

26 May 2020

Inventor of hepatitis C cure wins prestigious award from University of Edinburgh

A medicinal chemist who found a cure for the viral disease hepatitis C has received a prestigious award from the University of Edinburgh.

3 May 2020

Racial inequalities in liver cancer mortality increased after introduction of hepatitis C drugs

In the United States, hepatocellular or liver cancer deaths have doubled since 1979. Hepatitis C virus is the leading cause of liver cancer.

30 Apr 2020

Research shows how the immune system reacts to hepatitis C viruses

If a virus penetrates a cell, the immune system reacts immediately and produces the signaling protein interferon.

24 Apr 2020

Using 'own' immune cells to fight infectious diseases including COVID-19

A provocative paper from Duke-NUS Medical School, published in the Journal of Experimental Medicine in March 2020, discusses the possibilities of creating new receptors on a sick person's own immune cells as a means of controlling the infection. This therapy is already being used to treat certain cancers with marked success.

22 Apr 2020

Researchers are exploring potential therapy for controlling infectious diseases

The engineering of specific virus-targeting receptors onto a patient's own immune cells is now being explored by scientists from Duke-NUS Medical School (Duke-NUS), as a potential therapy for controlling infectious diseases, including the COVID-19-causing virus, SARS-CoV-2.

22 Apr 2020

Remdesivir drug stops novel coronavirus from replicating

Scientists from the University of Alberta have published findings that the antiviral drug remdesivir prevents replication of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by inhibiting RNA replication. The study, published in April 2020 in the Journal of Biological Chemistry, follows on the heels of earlier reports from the same lab in February, showing the drug's effectiveness against the related Middle East Respiratory Syndrome (MERS) virus.

15 Apr 2020

Ebola drug effective against key enzyme of coronavirus that causes COVID-19

Scientists at the University of Alberta have shown that the drug remdesivir is highly effective in stopping the replication mechanism of the coronavirus that causes COVID-19, according to new research published today in the Journal of Biological Chemistry.

13 Apr 2020

Research reveals rising rates of liver cancer

New research reveals rising rates of liver cancer around the world, despite advances aimed at preventing the disease. The findings are published early online in CANCER, a peer-reviewed journal of the American Cancer Society.

23 Mar 2020

Updated USPSTF recommendations on hepatitis C screening

The U.S. Preventive Services Task Force (USPSTF) now recommends the hepatitis C virus (HCV) infection screening for adults in the age group 18 to 79 years. This update comes against the background of increasing HCV over the last ten years, primarily due to higher injection drug use, and closer monitoring. The recommendation ensures that this screening will be covered by insurance as well without cost-sharing.

2 Mar 2020

New direct-acting antiviral therapies effectively target Hepatitis C virus

New direct-acting antiviral therapies are highly effective at eliminating the Hepatitis C virus infection, according to a systematic evidence review by researchers at Oregon Health & Science University.

2 Mar 2020

Drug for Ebola and MERS effective against COVID-19

A new study published in the Journal of Biological Chemistry has revealed that drug Remdesivir could be useful in treating the deadly COVID-19 or the novel coronavirus that is infecting tens of thousands of people across the world.

1 Mar 2020

Study finds inadequate testing for Tennessee infants exposed to hepatitis C

Most Tennessee infants exposed to hepatitis C at birth are not later tested to see if they acquired the virus, according to a study by researchers at Monroe Carell Jr. Children's Hospital at Vanderbilt and the Vanderbilt Center for Child Health Policy.

14 Feb 2020